Recent News

• 06.01.2026 - Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
• 05.28.2026 - Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
• 05.26.2026 - Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
• 05.15.2026 - Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Recent Filings

• 05.29.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 05.29.2026 - 8-K Current report
• 05.28.2026 - 8-K Current report
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 05.26.2026 - EX-99.1 EX-99.1
• 05.26.2026 - 8-K Current report
• 05.22.2026 - PRE 14A Other preliminary proxy statements